|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||153.79 - 155.88|
|52 Week Range||118.10 - 165.14|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||23.91|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||169.69|
The average healthcare stock in the S&P; 1500 Index has returned 8% including dividends this year, just below the broad index's average total return of 9%, explains Richard Moroney, editor of Dow Theory Forecasts.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present at Baird’s 2019 Global Healthcare Conference on Thursday, September 5, 2019. ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of ICON Plc and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.60% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICON Public Limited Company (ICLR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that it will present DIA Live – a social media aggregation site that allows visitors to track and analyse Twitter conversations from delegates at the DIA Global Annual Meeting (23 - 27 June, San Diego, CA).
ICON PLC NASDAQ/NGS:ICLRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ICLR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ICLR. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $38 million over the last one-month into ETFs that hold ICLR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as ICON Public Limited...
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a majority shareholding in MeDiNova Research, a site network with research sites in key markets in Europe and Africa, and that it has the right to acquire the remaining shares in the company by Quarter 3 2020. The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.